Latest Issue

Volume 1 Issue 4

Paper of the Month

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

Wilschanski M, Miller LL, Shoseyov D et al.
Hadassah University Hospital, Jerusalem, Israel.
Eur Respir J 2011;38:59–69.
Editor’s note: Ataluren (PTC124) is an orally bioavailable drug that induces selective ribosomal read-through of mRNA containing a premature stop codon, thereby allowing the translation of full-length protein. In the present study, Wilschanski et al. investigate the effects of long-term ataluren treatment in a group of CF patients with stop mutations.
» Read an expert review of this paper

Webcast

Our most popular articles

Latest news

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home

READER POLL

Cystic Fibrosis 1
In your opinion, which of the following would make up the ideal protocol for newborn screening for cystic fibrosis?







Powered by NetPolls

READER SURVEY

SUBMIT AN ARTICLE

OTHER REMEDICA JOURNALS

COMPASS PUBMED SEARCH

Enter your search terms below to search pubmed for articles